US Resident
+ Font size - | Print Print | Email to a Friend Email to a Friend | Prescribing Information & Boxed Warning
Skip Navigation Links > Home > Oncology > Efficacy Safety > Lung Cancer > Taxotere® Benefits
Learn more about The PACT+ SM Program.
Keep dosing at your fingertips

Pre-med sheets for Breast, Lung, Prostate, Gastric, and Head and Neck Cancer.

Lung Cancer and Taxotere®

Locally Advanced or Metastatic Non–Small-Cell Lung Cancer after failure of platinum-based chemotherapy (second-line)

In clinical trials including patients with locally advanced or metastatic non–small-cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy, Taxotere® (docetaxel) has demonstrated the following benefits vs. best supportive care (BSC) and vinorelbine (V) or ifosfamide (I):

  • Proven survival: The Taxotere® group demonstrated longer median survival than the BSC group (7.5 months vs. 4.6 months, respectively; P=.01) TAX3171 and the vinorelbine or ifosfamide group (5.7 months vs. 5.6 months, respectively; P=.13.NS) TAX3201
  • Preservation of performance status: The Taxotere® group showed a significantly smaller amount of deterioration in Eastern Cooperative Oncology Group (ECOG) performance status vs. BSC (0.65 mean decrease vs. 1.09 mean decrease, respectively; P≤.05) TAX3171
  • Preservation of weight: 98% of patients receiving Taxotere® did not experience >10% weight loss, vs. 78% of BSC patients.1-3

Unresectable, Locally Advanced or Metastatic Non-Small-Cell-Lung Cancer who have not previously received chemotherapy for this condition (first-line)

In clinical trials including patients with unresectable, locally advanced or metastatic NSCLC, first-line therapy with Taxotere® + cisplatin has demonstrated the following benefits vs. vinorelbine + cisplatin:

  • Proven survival: The Taxotere® + cisplatin group demonstrated longer median survival than the vinorelbine + cisplatin group (10.9 months vs. 10.0 months, respectively; P=.122(NS) TAX3171
  • Proven tumor response: The Taxotere® + cisplatin group also demonstrated a higher overall response rate than the vinorelbine + cisplatin group (31.6% vs. 24.4%, respectively; P=NS) TAX3201
  • Proven survival in patients age 65 and older: In this patient population, median survival with Taxotere® + cisplatin was 12.1 months.
  • More patients in the Taxotere® + cisplatin group completed all 6 cycles of therapy vs. patients in the vinorelbine + cisplatin (49.8% vs. 33.6%, respectively).1,4
Well Established Safety Profile

Treatment-emergent adverse events in Tax 317 and Tax 320

Grade 3/4 adverse events
Adverse event Taxotere® 75 mg/m2
(n=176)
% of patients		 BSC
(n=49)
% of patients		 V/I
(n=119)
% of patients
Hematologic Neutropenia 65.3 12.2 57.1
Febrile neutropenia 6.3 N/A* 0.8
Leukopenia 49.4 0 42.9
Thrombocytopenia 2.8 0 1.7
Anemia 9.1 12.2 14.3
Infection 10.2 6.1 9.2
Non-hematologic Hypersensitivity reactions 2.8 0 0
Fluid retention (severe) 2.8 N/D† 3.4
Neurosensory 1.7 6.1 5.0
Neuromotor 4.5 6.1 3.4
Skin 0.6 2.0 0.8
Nausea 5.1 4.1 7.6
Vomiting 2.8 2.0 5.9
Diarrhea 2.8 0 4.2
Asthenia‡ 18.2 38.8 22.7
Stomatitis 1.7 0 0.8
Pulmonary 21.0 28.6 18.5
Nail disorder‡ 1.1 0 0
Myalgia‡ 0 0 0
Arthralgia‡ 0 0 0.8
Taste perversion‡ 0.6 0 0
Treatment-related mortality 2.8 N/A* 3.4
* Not applicable
† Not done.
‡ Classified as "severe" by the COSTART grading system.

Learn more about clinical trials demonstrating the benefits of Taxotere® in the treatment of lung cancer.

Also, access Taxotere® dosing adjustment guidelines for lung cancer patients, useful resources for you in your practice, and educational materials for your patients.

References

  1. Taxotere® Prescribing Information. Bridgewater, NJ: sanofi-aventis U.S. LLC; Rev.December 2006
  2. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
  3. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non–small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354-2362.
  4. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non–small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol. 2003;21:3016-3024.
Prescribing Information | Site Map | Terms of Use | Privacy Policy | Contact Us
© 2002- 2008 sanofi-aventis U.S. LLC. All rights reserved.
Legal Disclaimer Information and Privacy Policy
Questions or Comments? Click here to contact us.
This site intended for use by U.S. residents only.
US.DOC.07.09.021  Last update:  October 2007
WARNING
  • The incidence of treatment-related mortality associated with Taxotere® therapy is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive Taxotere® as a single agent at a dose of 100 mg/m2 (see WARNINGS section of the prescribing information)
  • Taxotere® should generally not be given to patients with bilirubin > upper limit of normal (ULN), or to patients with serum glutamic-oxaloacetic transaminase (SGOT) and/or serum glutamic-pyruvic transaminase (SGPT) > 1.5 X ULN concomitant with alkaline phosphatase > 2.5 X ULN
    • Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of grade 4 neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death
    • Patients with isolated elevations of transaminase > 1.5 X ULN also had a higher rate of febrile neutropenia grade 4 but did not have an increased incidence of toxic death
    • Bilirubin, SGOT or SGPT, and alkaline phosphatase values should be obtained prior to each cycle of Taxotere® therapy and reviewed by the treating physician
  • Taxotere® therapy should not be given to patients with neutrophil counts of < 1500 cells/mm3
    • In order to monitor the occurrence of neutropenia, which may be severe and result in infection, frequent blood-cell counts should be performed on all patients receiving Taxotere®
  • Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or very rarely fatal anaphylaxis, have been reported in patients who received the recommended 3-day dexamethasone premedication
    • Patients should be observed closely for hypersensitivity reactions, especially during the first and second infusions
  • Taxotere® must not be given to patients who have a history of severe hypersensitivity reactions to Taxotere® or to other drugs formulated with polysorbate 80
    • All patients should be premedicated with oral corticosteroids such as dexamethasone (see DOSAGE AND ADMINISTRATION section of the prescribing information)
  • Severe fluid retention occurred in 6.5% (6/92) of patients despite use of a 3-day dexamethasone premedication regimen. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) (see PRECAUTIONS section of the prescribing information)

Additional Warnings
  • Treatment-related acute myeloid leukemia (AML) or myelodysplasia has occurred in patients given anthracyclines and/or cyclophosphamide, including use with Taxotere® in adjuvant therapy of breast cancer

  • Taxotere® can cause fetal harm when administered to pregnant women. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with Taxotere®


    • Precautions
  • Localized erythema of the extremities with edema followed by desquamation has been observed

    • — In case of severe skin toxicity, an adjustment in dosage is recommended (see DOSAGE AND ADMINISTRATION section of the prescribing information)
  • Severe neurosensory symptoms (paresthesia, dysesthesia, pain) were observed in 5.5% (53/965) of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%

    • — When these symptoms occur, dosage must be adjusted; if symptoms persist, treatment should be discontinued (see DOSAGE AND ADMINISTRATION section of the prescribing information)
  • Severe asthenia was reported in 14.9% (144/965) of metastatic breast cancer patients, but led to treatment discontinuation in only 1.8%

    • — Symptoms of fatigue and weakness may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease
  • In patients treated with TCF for gastric cancer, the incidence of serious adverse events was higher in patients ≥65 years than in younger patients. Adverse events (all grades) occurring at rates ≥10% higher in elderly patients included lethargy, stomatitis, diarrhea, dizziness, edema, and febrile neutropenia/neutropenic infection.

  • Taxotere® should be administered only under the supervision of a qualified physician experienced in the use of antineoplastic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available

    • Please see important safety information and full prescribing information, including boxed WARNING.

    Taxotere Indications

    Breast Cancer
    TAXOTERE® is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy
    TAXOTERE® in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer

    Non-Small Cell Lung Cancer
    TAXOTERE®, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy
    TAXOTERE® in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic NSCLC who have not previously received chemotherapy for this condition.

    Prostate Cancer
    TAXOTERE® in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

    Gastric Cancer
    TAXOTERE® in combination with cisplatin and flouroucil is indicated for the treatment of patients with advanced gastric adenocercinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.

    Head and neck Cancer
    TAXOTERE® in combination with cisplatin and flourouracil is indicated for the induction treatment of patients with locally advanced squamous cell cercinoma of the head and neck (SCCHN).